Published in Vaccine Weekly, July 21st, 2004
"'Cross-priming' describes the activation of naive CD8+ T cells by professional antigen-presenting cells that have acquired viral or tumor antigens from 'donor' cells. Antigen transfer is believed to be mediated by donor cell-derived molecular chaperones bearing short peptide ligands generated by proteasome degradation of protein antigens. We show here that cross-priming is based on the transfer of proteasome substrates rather than peptides," investigators in the United States report.
"These findings are potentially important for the rational design of vaccines that elicit CD8+ T...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.